ACRS - CIK 0001557746
The table below shows Aclaris Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$47.11M | -$20.07M | -$78.33M | -$67.57M | -$52.13M | -$38.63M |
| Capital expenditure | $111.00K | $121.00K | $1.31M | $605.00K | $308.00K | $453.00K |
| Investing cash flow | $48.37M | -$69.77M | $46.22M | $12.63M | -$167.63M | $6.39M |
| Dividends paid | - | - | - | - | - |
Aclaris Therapeutics, Inc. reported operating cash flow of -$47.11M for fiscal year 2025. That is down 134.7% from -$20.07M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$34.60M (FY 2016) to -$47.11M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$5.86M | $74.54M | $26.71M | $72.87M | $225.05M | $18.37M |